Information management systems for pharmacogenomics.

Abstract:

:The value of high-throughput genomic research is dramatically enhanced by association with key patient data. These data are generally available but of disparate quality and not typically directly associated. A system that could bring these disparate data sources into a common resource connected with functional genomic data would be tremendously advantageous. However, the integration of clinical and accurate interpretation of the generated functional genomic data requires the development of information management systems capable of effectively capturing the data as well as tools to make that data accessible to the laboratory scientist or to the clinician. In this review these challenges and current information technology solutions associated with the management, storage and analysis of high-throughput data are highlighted. It is suggested that the development of a pharmacogenomic data management system which integrates public and proprietary databases, clinical datasets, and data mining tools embedded in a high-performance computing environment should include the following components: parallel processing systems, storage technologies, network technologies, databases and database management systems (DBMS), and application services.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Thallinger GG,Trajanoski S,Stocker G,Trajanoski Z

doi

10.1517/14622416.3.5.651

keywords:

subject

Has Abstract

pub_date

2002-09-01 00:00:00

pages

651-67

issue

5

eissn

1462-2416

issn

1744-8042

pii

PGS030510

journal_volume

3

pub_type

杂志文章,评审
  • Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine.

    abstract::Randomized controlled trials are the gold standard for determining the efficacy of therapeutic interventions. However, medical practice has not evolved around the concept of randomized trials, but around the idea of careful observations, (anecdotal) case studies and the evaluation of retrospective data. Interventions ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.62

    authors: Frueh FW

    更新日期:2009-07-01 00:00:00

  • Rethinking ovarian cancer genomics: where genome-wide association studies stand?

    abstract::Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease susceptibility and 46 with impact in the clinical outcome of patients (p < 5.00 × 10-...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2017-0108

    authors: Pinto R,Assis J,Nogueira A,Pereira C,Pereira D,Medeiros R

    更新日期:2017-11-01 00:00:00

  • Pharmacogenomics of episodic migraine: time has come for a step forward.

    abstract::Migraine is characterized by heterogeneous behavior in response to drugs. Many resources have been invested in attempting to unravel the genetic basis of migraine, while the role of genetics in responses to currently available drugs has received less attention. We performed a systematic literature search identifying o...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.20

    authors: Viana M,Terrazzino S,Genazzani AA,Grieco GS,Cargnin S,Santorelli FM,Pierelli F,Tassorelli C,Nappi G,Di Lorenzo C

    更新日期:2014-03-01 00:00:00

  • Genomic architecture of pharmacological efficacy and adverse events.

    abstract::The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-base...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.144

    authors: Chhibber A,Kroetz DL,Tantisira KG,McGeachie M,Cheng C,Plenge R,Stahl E,Sadee W,Ritchie MD,Pendergrass SA

    更新日期:2014-12-01 00:00:00

  • Gene expression correlates of unexplained fatigue.

    abstract::Quantitative trait analysis (QTA) can be used to test whether the expression of a particular gene significantly correlates with some ordinal variable. To limit the number of false discoveries in the gene list, a multivariate permutation test can also be performed. The purpose of this study is to identify peripheral bl...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.7.3.395

    authors: Whistler T,Taylor R,Craddock RC,Broderick G,Klimas N,Unger ER

    更新日期:2006-04-01 00:00:00

  • Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples.

    abstract::The aim of this work was to determine the VKORC1 haplotype profile in healthy Hungarian and Roma population samples, and to compare our data with other selected populations. Using haplotype tagging SNPs (G-1639A, G9041A and C6009T), we characterized Hungarian (n = 510) and Roma (n = 451) population samples with regard...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.46

    authors: Sipeky C,Csongei V,Jaromi L,Safrany E,Polgar N,Lakner L,Szabo M,Takacs I,Melegh B

    更新日期:2009-06-01 00:00:00

  • Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy.

    abstract::Migraine is a paroxysmal neurological disorder affecting up to 6% of males and 18% of females in the general population, and has been demonstrated to have a strong, but complex, genetic component. Genetic investigation of migraine provides hope that new targets for medications and individual specific therapy will be d...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.6.609

    authors: Fernandez F,Colson NJ,Griffiths LR

    更新日期:2007-06-01 00:00:00

  • Pharmacogenetics in clinical practice: how far have we come and where are we going?

    abstract::Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.52

    authors: Johnson JA

    更新日期:2013-05-01 00:00:00

  • Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD.

    abstract::Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0120

    authors: Sissung TM,Cordes L,Peer CJ,Gandhy S,Redman J,Strauss J,Figg WD

    更新日期:2021-01-01 00:00:00

  • Parkinson's disease pharmacogenomics: new findings and perspectives.

    abstract::Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.93

    authors: Schumacher-Schuh AF,Rieder CR,Hutz MH

    更新日期:2014-06-01 00:00:00

  • Microarray expression technology: from start to finish.

    abstract::The recent introduction of new microarray expression technologies and the further development of established platforms ensure that the researcher is presented with a range of options for performing an experiment. Whilst this has opened up the possibilities for future applications, such as exon-specific arrays, increas...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.1.123

    authors: Elvidge G

    更新日期:2006-01-01 00:00:00

  • Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

    abstract:AIMS:The importance of polymorphisms in the dihydropyrimidine dehydrogenase gene (DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU)-based chemotherapy is still unclear. This study aims to assess the predictive value of DPYD variation with respect to previously described DPYD variants for 5-FU toxicit...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.28

    authors: Amstutz U,Farese S,Aebi S,Largiadèr CR

    更新日期:2009-06-01 00:00:00

  • Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.

    abstract:INTRODUCTION:Marked lowering of low-density-lipoprotein cholesterol (LDL-C) levels (< or =50%) with intensive statin therapy is associated with major reduction in cardiovascular risk, but is limited by a potential increase in adverse effects, thereby justifying optimization of LDL-C reduction with minimal risk. The org...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2217/14622416.9.9.1217

    authors: Couvert P,Giral P,Dejager S,Gu J,Huby T,Chapman MJ,Bruckert E,Carrié A

    更新日期:2008-09-01 00:00:00

  • Candidate gene analysis of pharmacodynamic targets for antipsychotic dosage.

    abstract:AIM:In order to administer antipsychotic medication with the most beneficial outcome, the appropriate drug and dose needs to be identified. Though often not considered in pharmacogenetic studies, dosage plays an important role in treatment outcome. This study set out to analyze the association between 109 SNPs and anti...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.171

    authors: Hettige NC,de Moraes GH,Kennedy JL,De Luca V

    更新日期:2016-02-01 00:00:00

  • miRNAs: from neurogeneration to neurodegeneration.

    abstract::miRNAs are reported to sequence-specifically control the translation of target mRNAs by binding to 3 UTRs. The abundant expression of miRNAs in the brain highlights their biological significance in neurodevelopment. Many studies have shown that miRNAs are involved in a variety of functions, including developmental tra...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.8.971

    authors: Singh SK

    更新日期:2007-08-01 00:00:00

  • Big data in pharmacogenomics: current applications, perspectives and pitfalls.

    abstract::The efficiency of new generation sequencing methods and the reduction of their cost has led pharmacogenomics to gradually supplant pharmacogenetics, leading to new applications in personalized medicine along with new perspectives in drug design or identification of drug response factors. The amount of data generated i...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0184

    authors: Barrot CC,Woillard JB,Picard N

    更新日期:2019-06-01 00:00:00

  • Advancing psychiatric pharmacogenomics using drug development paradigms.

    abstract::Drugs used to treat psychiatric disorders, even when taken as directed, fail to provide adequate relief for a sizeable proportion of patients. Despite our advancements in understanding human genetics and development of high-throughput tools to probe variation, pharmacogenomics has yielded marginal ability to predict d...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2017-0104

    authors: Smith RM

    更新日期:2017-10-01 00:00:00

  • Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis.

    abstract:AIM:Tamoxifen is one of the most commonly used endocrine therapeutic agents for breast cancer. Although many studies have examined whether the treatment outcomes of tamoxifen for breast cancer differ according to CYP2D6 genotype, the study results have been inconsistent, and the role of CYP2D6 in the prediction of pati...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.13.221

    authors: Jung JA,Lim HS

    更新日期:2014-01-01 00:00:00

  • SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis.

    abstract:AIM:Approximately a third of newly diagnosed epilepsy patients do not respond to antiepileptic drugs (AEDs). Evidence suggests that low penetrance variants in the genes of drug targets such as voltage-gated sodium channels may be involved in drug responsiveness. To examine this hypothesis, we compared data from two epi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析,多中心研究

    doi:10.2217/pgs.13.104

    authors: Haerian BS,Baum L,Kwan P,Tan HJ,Raymond AA,Mohamed Z

    更新日期:2013-07-01 00:00:00

  • Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.

    abstract:INTRODUCTION:Warfarin is a widely prescribed, efficacious oral anticoagulant. S-warfarin, the more active form, is metabolized by the cytochrome P450 (CYP)2C9 enzyme. The aim was to evaluate the influence of two CYP2C9 functional polymorphisms (*2 and *3) on warfarin dose in African-Americans, an unstudied population a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.3.217

    authors: Kealey C,Chen Z,Christie J,Thorn CF,Whitehead AS,Price M,Samaha FF,Kimmel SE

    更新日期:2007-03-01 00:00:00

  • Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications.

    abstract::Second-generation antipsychotics can greatly improve symptoms of psychosis-spectrum disorders. Unfortunately, these drugs are associated with weight gain, which increases a patient's risk for developing chronic diseases including Type 2 diabetes, cardiovascular diseases or other obesity-related complications. There ar...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.11.45

    authors: Lee AK,Bishop JR

    更新日期:2011-07-01 00:00:00

  • Evaluation of a shared pharmacogenomics curriculum for pharmacy students.

    abstract:AIM:This national dissemination study evaluated pharmacy students' self-reported overall ability, self-efficacy and attitudes toward applying pharmacogenomics and perceptions of Pharmacogenomics Education Program, a shared pharmacogenomics curriculum. PATIENTS & METHODS:Following a series of train-the-trainer programs...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.181

    authors: Lee KC,Hudmon KS,Ma JD,Kuo GM

    更新日期:2015-01-01 00:00:00

  • Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarrays. 22-24 January 2001, Zurich, Switzerland.

    abstract::Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...

    journal_title:Pharmacogenomics

    pub_type:

    doi:10.1517/14622416.2.1.73

    authors: Jain KK

    更新日期:2001-02-01 00:00:00

  • Psychiatric pharmacists' perception on the use of pharmacogenomic testing in the mental health population.

    abstract:AIM:Pharmacogenomics could play a role in improving patient care, reducing adverse drug reactions and overall healthcare costs. However, whether it is utilized may be determined by how it is perceived by healthcare professionals, including pharmacists. METHODS:A cross-sectional web-based survey evaluated psychiatric p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.22

    authors: Shishko I,Almeida K,Silvia RJ,Tataronis GR

    更新日期:2015-01-01 00:00:00

  • Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico.

    abstract:AIM:CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about polymorphisms in CYP2C9 gene and pharmacological implications in Mexican indigenous populations. Thus, frequencies of CYP2C9*2 and CYP2C9*3 alleles were evaluated in indigenous groups located in northwest (Cora), center (Mazahua an...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0099

    authors: Sánchez-Pozos K,Rivera-Santiago C,García-Rodríguez MH,Ortiz-López MG,Peña-Espinoza BI,Granados-Silvestre MLÁ,Llerena A,Menjívar M

    更新日期:2016-11-01 00:00:00

  • Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder.

    abstract::The recent advent of induced pluripotent stem cells has enabled the study of patient-specific and disease-related neurons in vitro and has facilitated new directions of inquiry into disease mechanisms. With these approaches, we now have the possibility of correlating ex vivo cellular phenotypes with individual patient...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2016-0187

    authors: Watmuff B,Liu B,Karmacharya R

    更新日期:2017-04-01 00:00:00

  • Genomics-based drug design targets the AT-rich malaria parasite: implications for antiparasite chemotherapy.

    abstract::Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...

    journal_title:Pharmacogenomics

    pub_type: 评论,杂志文章

    doi:10.2217/14622416.8.9.1267

    authors: Yanow SK,Purcell LA,Lee M,Spithill TW

    更新日期:2007-09-01 00:00:00

  • Codeine-induced acute generalized exanthematous pustulosis without IL36RN mutations.

    abstract::Recent studies have suggested an association between mutations in the IL-36RN gene and the onset of pustular generalized. In the literature, only one case of acute generalized exanthematous pustulosis (AGEP) induced by codeine in a patient with IL36RN mutation has been reported. Herein, we reported an unusual case of ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0200

    authors: Chadli Z,Ladhari C,Kerkeni E,Djobbi A,Fredj NB,Chaabane A,Boughattas NA,Aouam K

    更新日期:2018-07-01 00:00:00

  • Resequencing CYP2D6 gene in Indian population: CYP2D6*41 identified as the major reduced function allele.

    abstract::Aim: The CYP2D6 gene is highly polymorphic and harbors population specific alleles that define its predominant metabolizer phenotype. This study aimed to identify polymorphisms in Indian population owing to scarcity of CYP2D6 data in this population. Materials & methods: The CYP2D6 gene was resequenced in 105 south In...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0049

    authors: Manoharan A,Shewade DG,Ravindranath PA,Rajkumar RP,Ramprasad VL,Adithan S,Damodaran SE

    更新日期:2019-07-01 00:00:00

  • VBC-Genomics Bioscience Research GmbH (LLC).

    abstract::Founded as a spin-off from the University of Vienna in 1999, VBC-GENOMICS Bioscience Research GmbH (LLC) has rapidly gained a strong position within the Austrian biotech scene, based on its success as a service provider in oligonucleotide synthesis and custom sequencing. In research, the company has focused on the dev...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.5.4.439

    authors: Schmidt WM

    更新日期:2004-06-01 00:00:00